Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan

Overview

Phase II, randomized, double-blind, placebo-controlled study of the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 in the elderly in Taiwan

Full Title of Study: “Phase II, Randomized, Double-blind, Clinical Tial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Investigator)
  • Study Primary Completion Date: April 30, 2020

Detailed Description

In Taiwan, people who aged 50 to 70 years accounted for over 40% among those who infected by dengue virus every year. Therefore, to understanding the immunogenicity and safety of TV005 vaccine among people aged 50 to 70 years is important for whether TV005 can be introduced into Taiwan as a major intervention to control dengue. This trial is a phase II, double-blind, multicenter, and placebo-controlled one. The investigators plan to enroll 252 subjects whose age are 50 to 70 years at four study sites. One single-dose TV005 vaccine or placebo will be given subcutaneously. After vaccination, detailed data of the subjective symptoms, physical examination, laboratory examination, and titer of neutralization antibody from all subjects will be recorded. After completion of the present trial, the investigators can clarify the immunogenicity and safety of TV005 among people aged 50 to 70 years.

Interventions

  • Biological: Tetravalent live attenuated dengue vaccine admixture TV005
    • The admixtures of the candidate vaccines each contain 4 live attenuated dengue viruses, each of a different serotype.
  • Biological: Placebo
    • PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.

Arms, Groups and Cohorts

  • Experimental: Tetravalent live attenuated dengue vaccine admixture TV005
    • Tetravalent live attenuated dengue vaccine admixture TV005
  • Placebo Comparator: placebo
    • Plasma-Lyte A

Clinical Trial Outcome Measures

Primary Measures

  • Proportion of study participants with solicited local and general adverse events.
    • Time Frame: Measured through Day 21
  • Proportion of study participants with unsolicited adverse events.
    • Time Frame: Measured through Day 29
  • Proportion of study participants with serious adverse events.
    • Time Frame: Measured through Day 1080
  • Evaluation of the immunogenicity of TV005, as assessed by PRNT50 to DENV-1, DENV-2, DENV-3, and DENV-4 at 0, 28, 56, 72 and 180 days after TV005 vaccination
    • Time Frame: Measured through Day 180

Secondary Measures

  • Evaluation of the frequency and quantity of viremia of each monovalent component of the vaccine after vaccination.
    • Time Frame: Measured through Day 21
  • Number of TV005 vaccinees infected with DENV-1, DENV-2, DENV-3, and DENV-4.
    • Time Frame: Measured through Day 72

Participating in This Clinical Trial

Inclusion Criteria

1. Man or non-pregnant / non-lactating woman between the ages of 50 years and 70 years at the time of enrollment into the study.

2. Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits).

3. Subject who allow to access to their Medical Record.

4. Subjects whose residence is in Taiwan who will remain available for the duration of the study, approximately 3 years following the first vaccination.

5. Good general health as determined by physical examination, laboratory screening, and review of medical history.

6. An informed consent form signed and dated by the subject.

7. If the subject is female, she must be of non-childbearing potential, i.e. surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (i.e. intrauterine contraceptive device; condom and spermicide combination, oral contraceptives or other equivalent hormonal contraception, e.g. progestin implantable, cutaneous hormonal patch or injectable contraceptives) for 30 days prior to vaccination, have a negative pregnancy test prior to vaccination and must agree to continue such precautions for 90 days after completion of the vaccination. For male subject, he must be abstinent or use a condom together with spermicide for 14 days after completion of the vaccination.

Exclusion Criteria

1. Pregnant or lactating female or female planning to become pregnant within 90 days of receiving an investigational product or planning to discontinue abstinence or contraceptive precautions within 90 days of receiving an investigational product.

2. Acute or chronic, clinically significant neurological, pulmonary, cardiovascular, hepatic, renal, autoimmune, hematologic, endocrine disease or functional defect, as determined by history, physical examination or screening tests that in the opinion of the investigator would, will jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol.

3. Psychiatric, behavioral disorder, or seizures (with the exception of a single febrile seizure in childhood) that in the opinion of the investigator, will affect the ability of the subject to understand and cooperate with the requirements of the study protocol.

4. Self-reported or suspected congenital or acquired immunodeficiency, or asplenia; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent, ≥ 0.5 mg/kg/day or 20 mg/day, for more than 2 consecutive weeks within the past 3 months). Inhaled and topical steroids are allowed.

5. HIV infection by screening (by HIV Ag/Ab combo test or HIV Ab test) and confirmatory assays (by Western blot), Hepatitis C virus (HCV) infection by Anti-HCV Ab, or Hepatitis B virus (HBV) infection by Hepatitis B surface antigen (HBsAg) screening or, unwilling to allow HIV, HCV and HBV testing.

6. Screening laboratory values of hemoglobin <9.5 gm/dL in female adults or <11 gm/dL in male adults, neutrophil <1,000 mm3, platelet < 100,000/mm3, Creatinine >1.5 mg/dL, Bilirubin-T >1.5 times of upper limit, or ALT > 2 times of upper limit.

7. History of allergic disease/reaction likely to be exacerbated by any component of the vaccine; or any history of a severe allergic reaction or anaphylaxis.

8. Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures.

9. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol.

10. Planned administration of any vaccine not foreseen by the study protocol, during the period starting from 30 days before the study vaccine and ending 30 days after study vaccination; with the exceptions of the inactivated influenza vaccine or the inactivated rabies vaccine (without administration of immunoglobulin) administered.

11. Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the study vaccine/placebo or planned use at any time during the study period or history of having received any investigational dengue vaccine at any previous time.

12. Administration of immunoglobulins and/or blood products within 90 days preceding the study vaccine dose or planned administration at any time during the study period, which might interfere with assessment of the immune response. Or administration of killed vaccine within 14 days, or attenuated vaccine within 28 days.

13. A planned or anticipated move to a location that will prohibit participating in the trial for the 12 month duration and unavailable for schedule visit during 2nd and 3rd year follow-up.

14. Potential volunteers who do not have easy access to a fixed or mobile telephone.

15. Any subject identified as a site employee of the Investigator or study clinic, with direct involvement in the proposed study or other studies under the direction of that Investigator or study clinic, as well as any family member (i.e., immediate, husband, wife and their children, adopted or natural) of the clinic employees or the Investigator.

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • National Taiwan University Hospital
  • Collaborator
    • Centers for Disease Control, Taiwan
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Shan-Chwen Chang, +886-2-2312-3456, changsc@ntu.edu.tw

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.